Monday, December 01, 2008 Free Registration Log-in to View Profiles
Empire Relations Group is a Premier Investor Relations Organization representing publicly-traded companies in their communications programs with existing shareholders and potential investors.
investments
OTCBB
OTCBB
Pressroom 
 
 Archived
 
 Non-Public Companies
 Consumer
 Energy, Environment & Natural Resources
 Financials
 Healthcare/BioTech
 Industrials
 IT & Computers
 Materials
 Telecommunications
 Utilities
 
 Public Companies
 Consumer
 Energy, Environment & Natural Resources
 Financials
 Healthcare/BioTech
 Industrials
 IT & Computers
 Materials
 Telecommunications
 Utilities
Search


Public Companies : Healthcare/BioTech


Smith & Nephew Plc - Transaction in Own Shares

Jun 27, 2008 - 11:36:01 AM

News Source MARKET WIRE

Email this article
 Printer friendly page
London, UK -- (MARKET WIRE) -- 06/27/08 --

Transaction in own shares.Smith & Nephew plc announces that on 27 June 2008 it purchased 175,000ordinary shares of USUSD0.20 each at a price of 553.5769 pence per share.The purchased shares will be held as treasury shares.Following the above purchase, Smith & Nephew plcholds 63,474,483 ordinary shares in treasury, andhas 885,430,797 ordinary shares in issue (excluding treasury shares).Paul ChambersCompany Secretary                    This information is provided by RNS          The company news service from the London Stock ExchangeEND

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com



Top of Page | Main News Index | EmpireRelations.com Home Page EmpireRelations.com Selected Clients News

Come see our services. Copr. © 2005 Empire Relations Group, Inc.

Healthcare/BioTech
Latest Headlines
Rescinding the Ban on Embryonic Stem Cell Research: Experts Speak Out on What's Next for This Area of Biotechnology
Trinity Biotech Announces Success of Destiny Max Trials and First Orders From Japan
AVI BioPharma Strengthens Patent Position in Exon Skipping
Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA
Transaction in Own Shares
Heart Health Inc. Begins Process to Obtain FDA Approval for Heart Health Monitor
Third pivotal phase 3 study for NicOx' naproxcinod shows positive efficacy, safety and blood pressure results
Red Mountain Pharmaceuticals Inc. Merges With Zalemark Inc.
Given Imaging Announces French Health Ministry Finalizes Reimbursement for PillCam SB
Chemaphor Announces Proposed Private Placement